Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedra & stroke

This article was originally published in The Tan Sheet

Executive Summary

"Association between the use of ephedra-containing products and increased risk for hemorrhagic stroke" was not demonstrated in Hemorrhagic Stroke Project, L.B. Morgenstern, MD, University of Texas at Houston, et al., report in the January issue of Neurology. However, researchers note "analysis by dose suggests there may be an association with use of more than 32 mg/d" ephedra. Morgenstern et al. analyzed 702 subjects who enrolled between December 1994 and July 1999 in the HSP, which was designed to investigate association between phenylpropanolamine and hemorrhagic stroke risk. HSP findings eventually prompted FDA to request PPA marketers pull the ingredient off the market...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS095025

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel